Agios Pharmaceuticals (NASDAQ:AGIO) Earns Outperform Rating from Analysts at BMO Capital Markets

Share on StockTwits

BMO Capital Markets began coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Thursday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $45.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on AGIO. Zacks Investment Research upgraded Agios Pharmaceuticals from a sell rating to a hold rating and set a $46.00 price target for the company in a report on Wednesday, August 14th. BidaskClub downgraded Agios Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, September 6th. Goldman Sachs Group reiterated a neutral rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. Royal Bank of Canada set a $89.00 price target on Agios Pharmaceuticals and gave the company a buy rating in a report on Friday, August 2nd. Finally, Cowen reiterated a buy rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $68.57.

AGIO stock opened at $37.74 on Thursday. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -6.26 and a beta of 2.22. The company has a quick ratio of 5.91, a current ratio of 5.96 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $40.70 and a 200-day simple moving average of $51.34. Agios Pharmaceuticals has a 52 week low of $33.17 and a 52 week high of $79.17.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.87) EPS for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.17). The firm had revenue of $26.22 million for the quarter, compared to analyst estimates of $27.05 million. Agios Pharmaceuticals had a negative return on equity of 59.89% and a negative net margin of 383.05%. The company’s quarterly revenue was down 35.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.19) earnings per share. As a group, analysts expect that Agios Pharmaceuticals will post -7.12 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Dimensional Fund Advisors LP increased its holdings in Agios Pharmaceuticals by 27.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 182,150 shares of the biopharmaceutical company’s stock valued at $8,399,000 after purchasing an additional 39,255 shares in the last quarter. Geode Capital Management LLC boosted its position in Agios Pharmaceuticals by 14.6% in the 4th quarter. Geode Capital Management LLC now owns 546,568 shares of the biopharmaceutical company’s stock valued at $25,202,000 after buying an additional 69,603 shares during the last quarter. Comerica Bank purchased a new position in Agios Pharmaceuticals in the 1st quarter valued at about $871,000. State Board of Administration of Florida Retirement System boosted its position in Agios Pharmaceuticals by 1.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 74,257 shares of the biopharmaceutical company’s stock valued at $5,008,000 after buying an additional 860 shares during the last quarter. Finally, TD Asset Management Inc. boosted its position in Agios Pharmaceuticals by 26.6% in the 1st quarter. TD Asset Management Inc. now owns 52,668 shares of the biopharmaceutical company’s stock valued at $3,552,000 after buying an additional 11,068 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Recommended Story: LIBOR

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research
Renewable Energy Group  Rating Increased to Hold at Zacks Investment Research
Renewable Energy Group Rating Increased to Hold at Zacks Investment Research


 
© 2006-2019 Zolmax.